| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| Imara Dives Into Coronavirus-Churned Financial Waters With a $75M IPO | Frank Vinluan | 03/12/20 | Boston |
| Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic | Frank Vinluan | 02/18/20 | Boston |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| La Jolla Pharma’s Share Price Halves On Trial End, CEO Departure | Sarah de Crescenzo | 11/26/19 | San Diego |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval | Frank Vinluan | 11/08/19 | New York |
| Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs | Frank Vinluan | 09/27/19 | Boston |
| Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further | Ben Fidler | 09/23/19 | Boston |
| Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System | Frank Vinluan | 09/10/19 | San Francisco |
| Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes | Frank Vinluan | 09/03/19 | Boston |
| Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood Disease | Frank Vinluan | 06/14/19 | Boston |
| Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More | Alex Lash | 06/07/19 | National |
| Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval | Frank Vinluan | 06/03/19 | Boston |
| Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera | Ben Fidler | 05/15/19 | Boston |
| ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups | Frank Vinluan | 05/13/19 | Boston |
| Celgene Files for FDA Approval of Blood Disease Drug | Frank Vinluan | 04/05/19 | New York |
| Panel Nod Moves Bluebird’s Gene Therapy Closer to Europe’s Market | Ben Fidler | 03/29/19 | Boston |
| With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy | Ben Fidler | 01/31/19 | New York |
| ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On | Ben Fidler | 12/03/18 | National |
| Bio Roundup: CRISPR Babies, Blood Diseases, Big Cancer Nod & More | Alex Lash | 11/30/18 | National |
| ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More | Alex Lash | 11/26/18 | National |
| Orchard, Fueled by GSK’s Ex-Gene Therapy Biz, Nets $200M in IPO | Ben Fidler | 10/31/18 | Boston |
| Vertex Hums Along as AbbVie Snatches Up a Rival’s CF Drugs for $45M | Ben Fidler | 10/25/18 | Boston |
| CRISPR Therapeutics, Vertex Get FDA Green Light for Sickle Cell Test | Frank Vinluan | 10/10/18 | Boston |
| Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder | Frank Vinluan | 07/09/18 | Boston |
| Acceleron’s Blood Drug Hits Phase 3 Goals, Paves Way for FDA Filing | Frank Vinluan | 06/28/18 | Boston |
| Sarepta’s Data Are First in Rush for Duchenne Gene Therapy | Ben Fidler | 06/19/18 | Boston |
| For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs | Alex Lash | 06/15/18 | San Francisco |
